ResMed Files Patent Infringement Action against Fisher & Paykel
ResMed (NYSE: RMD) (ASX: RMD), the world’s leading tech-driven medical device company and innovator in sleep apnea and respiratory care, today filed a petition with the United States International Trade Commission to stop the infringement of its patented technology by New Zealand-based medical device manufacturer Fisher & Paykel Healthcare.
In the International Trade Commission, ResMed seeks an order banning the importation and sale in the United States of Fisher & Paykel’s Simplus full face mask, Eson nasal mask and Eson 2 nasal mask, for infringing five ResMed patents relating to mask system and cushion design. ResMed’s new case asserts that:
- F&P’s Simplus infringes each of the five asserted ResMed patents.
- F&P’s Eson and Eson 2 infringe three of the five patents, which relate to modular mask systems.
Also today, ResMed filed a new lawsuit in the United States District Court for the Southern District of California, seeking monetary damages based on Fisher & Paykel’s patent infringement, plus an injunction against future sales of infringing masks in the United States.
“ResMed provides millions of consumers with high-quality products, which are the direct result of substantial and sustained investments in research and development, as well as a focus on each consumer’s therapy needs,” said ResMed global general counsel and chief administrative officer David Pendarvis. “We will defend our intellectual property wherever necessary to ensure that patients worldwide continue to receive the high-quality care they deserve, and are confident that when the ITC and the District Court hear all the evidence, ResMed will prevail in these cases.”
ResMed (NYSE: RMD, ASX: RMD) changes lives with award-winning medical devices and cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 5 million patients remotely monitored every day. Our 6,000-strong team is committed to creating the world’s best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 120 countries. ResMed.com
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
CA-BLUE-DANUBE-SYSTEMS22.2.2019 00:02:10 | Pressemeddelelse
Blue Danube Systems Coherent Massive MIMO Delivers Industry’s Highest Capacity Gains in Multiple Commercial Networks
CA-BLUE-DANUBE-SYSTEMS21.2.2019 23:02:07 | Pressemeddelelse
Blue Danube Systems Expands Operations in India and Welcomes Sundeep Raina to the Global Sales Management Team
CA-BLUE-DANUBE-SYSTEMS21.2.2019 21:02:10 | Pressemeddelelse
Blue Danube Systems Enhances BeamPlanner™ Software Including Artificial Intelligence and Machine Learning Capabilities
HCL-TECHNOLOGIES21.2.2019 20:08:07 | Pressemeddelelse
Recipients of HCL GRANT 2019 Felicitated by Amitabh Kant & Sourav Ganguly
FPCF/FPCC21.2.2019 18:50:03 | Pressemeddelelse
International Indigenous Languages Conference Set for June in British Columbia
AXILUM-ROBOTICS21.2.2019 18:02:10 | Pressemeddelelse
Axilum Robotics Announces U.S. FDA 510(k) Clearance for TMS-Cobot
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum